Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1753 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-31

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors

NCT04619472

Lung Neoplasms Pulmonary Metastasis

COMPLETED NA

Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma

NCT01574729

Non-small Cell Lung Cancer

UNKNOWN PHASE2

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

NCT05053802

Multiple Primary Lung Cancer

RECRUITING PHASE2

High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer

NCT03598517

Non-small Cell Lung Cancer

UNKNOWN NA

Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion

NCT05291403

Non Small Cell Lung Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mitochondrial therapy with radiofrequency ablation

Group Type EXPERIMENTAL

Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation

Intervention Type OTHER

Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites

Surgery

Group Type ACTIVE_COMPARATOR

Surgery

Intervention Type PROCEDURE

Patients will be treated with surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation

Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites

Intervention Type OTHER

Surgery

Patients will be treated with surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.
* Patients with single nodule.
* Before IIB period according to the eighth edition of the TNM staging period.
* No mediastinal lymph node metastasis.
* No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
* Eastern Cooperative Oncology Group performance status of 0 to 1
* Sufficient organ functions

Exclusion Criteria

* Active bacterial or fungous infection.
* Simultaneous or metachronous (within the past 5 years) double cancers.
* Patients with contraindications to radiofrequency ablation and inability to complete treatment;
* Women during pregnancy or breast-feeding.
* Uncontrollable diabetes mellitus.
* Patients with severe heart, lung, kidney disease or other systemic diseases who have been judged to have a severe impact on survival or who are pre-assessed to be unable to tolerate thoracoscopic surgery

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No